Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 3:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 1,670 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Comparator Clear all
Terminated Phase 4 Interventional Results available

Lisdexamfetamine's Effect In ADHD in the Brain and Cognition

NCT02170298
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
12 Years to 30 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 25, 2026, 3:49 AM EDT
Completed Phase 3 Interventional

MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains

NCT01198834
View directory record Official record
Conditions
Ankle Sprains
Interventions
MRX-7EAT, Placebo, Lidocaine, Etodolac
Drug
Lead sponsor
MEDRx USA, Inc.
Industry
Eligibility
14 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
33
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Chico, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 25, 2026, 3:49 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Visual Retraining After Stroke

NCT06121219
View directory record Official record
Conditions
Vision Loss Partial, Vision; Loss, Both Eyes, Hemianopia Homonymous, Hemianopia, Quadrantanopia, Stroke, Ischemic, Stroke - Occipital Infarction, Cortical Blindness
Interventions
Training in the Blind Field
Device
Lead sponsor
University of Rochester
Other
Eligibility
21 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2032
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 25, 2026, 3:49 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus

NCT04418999
View directory record Official record
Conditions
Keratoconus, Dry Eye, Allergy
Interventions
dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly
Drug
Lead sponsor
Illinois College of Optometry
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 25, 2026, 3:49 AM EDT
Recruiting Not applicable Interventional

Randomized Evaluation of Natural Extract for Menopausal Wellness (RENEW)

NCT07834463
View directory record Official record
Conditions
Menopause, Hot Flashes
Interventions
Shatavari (Asparagus racemosus) Extract, Placebo
Dietary Supplement · Other
Lead sponsor
India Glycols Ltd
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Port Richey, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 25, 2026, 3:49 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis

NCT04791319
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Placebo, Bermekimab, Dupilumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Los Angeles, California • Santa Ana, California • Orange Park, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 25, 2026, 3:49 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Caldolor (IV Ibuprofen) in Hospitalized Adult Orthopedic Patients

NCT00470600
View directory record Official record
Conditions
Pain
Interventions
Caldolor, Normal Saline
Drug · Other
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Mobile, Alabama • Little Rock, Arkansas • Arcadia, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2015 · Synced Oct 25, 2026, 3:49 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of SNF472 for Calciphylaxis

NCT04195906
View directory record Official record
Conditions
Calciphylaxis, Calcific Uremic Arteriolopathy
Interventions
Experimental: SNF472, Placebo Comparator: Placebo, Experimatenl SNF472 (Open-label)
Drug
Lead sponsor
Sanifit Therapeutics S. A.
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
38
States / cities
Phoenix, Arizona • El Centro, California • Escondido, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 25, 2026, 3:49 AM EDT
Completed Phase 3 Interventional

TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions

NCT00371709
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
TAXUS Liberté-SR, TAXUS™ Express
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
40
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 25, 2026, 3:49 AM EDT
Completed Not applicable Interventional

Use of Platelet Rich Plasma Therapy for Acute Ankle Sprains in the Emergency Department

NCT01518335
View directory record Official record
Conditions
Sprain of Ankle
Interventions
Platelet rich plasma injection, Placebo Comparator: Placebo/Standard of Care
Procedure
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 25, 2026, 3:49 AM EDT
Terminated Phase 2 Interventional Results available

Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis

NCT00995449
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
KB003, Placebo Comparator
Biological · Other
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
11
States / cities
Stanford, California • Westlake Village, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 25, 2026, 3:49 AM EDT
Completed Phase 2 Interventional Results available

Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

NCT02014376
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
SD-101 dermal cream (3%), SD-101 Dermal Cream (6%), Vehicle (SD-101 0%)
Drug
Lead sponsor
Scioderm, Inc.
Industry
Eligibility
6 Months and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
7
States / cities
Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 25, 2026, 3:49 AM EDT
Completed Phase 3 Interventional Results available

Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers

NCT03471078
View directory record Official record
Conditions
Chemotherapy-induced Thrombocytopenia
Interventions
Avatrombopag, Placebo Oral Tablet
Drug
Lead sponsor
Sobi, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
14
States / cities
Anaheim, California • Bakersfield, California • Riverside, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 25, 2026, 3:49 AM EDT
Terminated Phase 2 Interventional Results available

A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD

NCT00457951
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Open-Label, Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride, ODSH
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Orange, California • Marietta, Georgia • Shreveport, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 25, 2026, 3:49 AM EDT
Completed Phase 2 Interventional Results available

A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy

NCT04656561
View directory record Official record
Conditions
Geographic Atrophy
Interventions
ANX007, Sham comparator
Drug · Other
Lead sponsor
Annexon, Inc.
Industry
Eligibility
50 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
45
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 3:49 AM EDT
Completed Phase 3 Interventional Results available

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

NCT05393037
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
V116, Placebo, PCV15, PPSV23, PCV15 - Part B
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Ft. Pierce, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 25, 2026, 3:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

GAL1704 for Cheek Augmentation and Correction of Midface Contour Deficiencies

NCT03700047
View directory record Official record
Conditions
Cheek Augmentation
Interventions
GAL1704, Juvederm Voluma
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
22 Years and older
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
15
States / cities
Los Angeles, California • Sacramento, California • Solana Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 25, 2026, 3:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People

NCT05541861
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg, BNT162b4 5 mcg, BNT162b4 10 mcg, BNT162b4 15 mcg, BNT162b4 30 mcg, BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
17
States / cities
Tempe, Arizona • Newport Beach, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 25, 2026, 3:49 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD

NCT01414153
View directory record Official record
Conditions
Exudative Age-related Macular Degeneration
Interventions
4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea, sham injection
Drug
Lead sponsor
Lpath, Inc.
Industry
Eligibility
50 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
44
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 25, 2026, 3:49 AM EDT
Suspended Phase 3 Interventional Accepts healthy volunteers

A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering

NCT01684657
View directory record Official record
Conditions
Stuttering
Interventions
Asenapine
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 25, 2026, 3:49 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Repurposing Dexmedetomidine as an Orally Administered Sleep Therapeutic

NCT02818569
View directory record Official record
Conditions
Sleep, Insomnia
Interventions
Dexmedetomidine, Saline Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 25, 2026, 3:49 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia

NCT00641745
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Lurasidone HCl, Risperidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
41
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 25, 2026, 3:49 AM EDT
Completed Phase 3 Interventional Results available

A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

NCT02518139
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
TD-4208, Tiotropium
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Easley, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 25, 2026, 3:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of NKTR-358 (LY3471851) in Healthy Participants

NCT04380324
View directory record Official record
Conditions
Healthy
Interventions
LY3471851, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 25, 2026, 3:49 AM EDT